Hester Biosciences Ltd
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.[1]
- Market Cap ₹ 1,872 Cr.
- Current Price ₹ 2,201
- High / Low ₹ 2,350 / 1,239
- Stock P/E 34.9
- Book Value ₹ 423
- Dividend Yield 0.50 %
- ROCE 15.2 %
- ROE 15.9 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 21.8%
- Company's working capital requirements have reduced from 80.2 days to 54.4 days
Cons
- Stock is trading at 5.20 times its book value
- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 333 | |
| 64 | 67 | 82 | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 246 | |
| Operating Profit | 25 | 34 | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 87 |
| OPM % | 28% | 34% | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 26% |
| 3 | 1 | 0 | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 19 | |
| Interest | 5 | 4 | 4 | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 11 |
| Depreciation | 6 | 6 | 7 | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 19 |
| Profit before tax | 18 | 25 | 31 | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 76 |
| Tax % | 26% | 23% | 26% | 36% | 28% | 25% | 31% | 26% | 30% | 34% | 27% | 24% |
| 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 57 | |
| EPS in Rs | 15.99 | 22.57 | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.30 | 22.21 | 32.31 | 65.41 |
| Dividend Payout % | 19% | 18% | 19% | 33% | 23% | 19% | 25% | 22% | 26% | 27% | 22% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 8% |
| 3 Years: | 26% |
| TTM: | 93% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -3% |
| 3 Years: | 9% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 76 | 93 | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 | 352 |
| 55 | 59 | 66 | 69 | 90 | 121 | 105 | 228 | 274 | 244 | 213 | 195 | |
| 20 | 25 | 25 | 35 | 32 | 65 | 78 | 74 | 116 | 126 | 126 | 123 | |
| Total Liabilities | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
| 60 | 65 | 102 | 110 | 145 | 143 | 133 | 237 | 259 | 240 | 233 | 411 | |
| CWIP | 33 | 36 | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 | 9 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 | 43 |
| 68 | 85 | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 | 215 | |
| Total Assets | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 19 | 35 | 38 | 47 | 37 | 58 | 9 | 24 | 48 | 65 | 64 | |
| -21 | -13 | -30 | -26 | -21 | -73 | -42 | -117 | -77 | -22 | -20 | -18 | |
| 7 | -7 | 2 | -11 | 3 | 19 | -18 | 112 | 42 | -26 | -52 | -49 | |
| Net Cash Flow | 5 | -1 | 6 | 1 | 28 | -17 | -2 | 3 | -12 | -0 | -7 | -3 |
| Free Cash Flow | 1 | 5 | 5 | 15 | 24 | -36 | 17 | -87 | -54 | 24 | 44 | 47 |
| CFO/OP | 100% | 74% | 102% | 100% | 92% | 86% | 105% | 43% | 63% | 112% | 123% | 90% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 72 | 95 | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 | 105 |
| Inventory Days | 431 | 627 | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 | 323 |
| Days Payable | 68 | 109 | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 | 110 |
| Cash Conversion Cycle | 434 | 614 | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 | 318 |
| Working Capital Days | 76 | 112 | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 | 54 |
| ROCE % | 15% | 19% | 19% | 20% | 26% | 16% | 18% | 14% | 9% | 9% | 10% | 15% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity (Vaccine Doses) Billion doses per annum |
|
||||||||||
| Permanent Employees (Standalone India) Count ・Standalone data |
|||||||||||
| Poultry Healthcare Revenue Share (Standalone) % ・Standalone data |
|||||||||||
| Total Vaccines in Portfolio Count ・Standalone data |
|||||||||||
| Number of Countries Served Count |
|||||||||||
| Number of Distributors in India Count ・Standalone data |
|||||||||||
| Poultry Vaccine Market Share in India % ・Standalone data |
|||||||||||
| Global PPR Vaccine Market Share % |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
- Closure of Trading Window 26 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Jun - Copies of newspaper advertisement for 39th Annual General Meeting
-
Business Responsibility and Sustainability Reporting (BRSR)
18 Jun - Hester Biosciences submitted its BRSR for year ended 31 March 2026.
- Intimation Of Record Date For Dividend And Meeting 18 Jun
-
Reg. 34 (1) Annual Report.
18 Jun - Hester Biosciences issued 39th AGM notice and annual report; AGM on 21 July 2026, dividend cut-off 14 July.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
May 2026Transcript PPT REC
-
Jan 2026TranscriptPPTREC
-
Nov 2025TranscriptPPT
-
Aug 2025TranscriptPPT
-
May 2025TranscriptPPT
-
Feb 2025TranscriptPPTREC
-
Oct 2024TranscriptPPT
-
Aug 2024TranscriptPPT
-
May 2024TranscriptPPTREC
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPT
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Oct 2018TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Jul 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
Business Overview[1]
Hester operates an integrated animal healthcare platform across Poultry Healthcare and Animal Healthcare, offering vaccines, therapeutics, feed supplements, diagnostics, and petcare products. It's portfolio serves poultry farmers, livestock producers, veterinarians, and pet owners through a combination of R&D, manufacturing, quality systems, technical services, and field support.